share_log

HC Wainwright & Co. Reiterates Buy on Cara Therapeutics, Maintains $3.6 Price Target

Benzinga ·  May 15 11:36

HC Wainwright & Co. analyst Oren Livnat reiterates Cara Therapeutics (NASDAQ:CARA) with a Buy and maintains $3.6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment